Cargando…

MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a newly identified autoimmune demyelinating disorder that is often associated with acute disseminated encephalomyelitis and usually occurs postinfection or postvaccination. Here we report a case of MOGAD after mRNA sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Yuki, Ohyama, Ayane, Kubota, Takafumi, Ikeda, Kensuke, Kaneko, Kimihiko, Takai, Yoshiki, Warita, Hitoshi, Takahashi, Toshiyuki, Misu, Tatsuro, Aoki, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922017/
https://www.ncbi.nlm.nih.gov/pubmed/35299613
http://dx.doi.org/10.3389/fneur.2022.845755
_version_ 1784669438938710016
author Matsumoto, Yuki
Ohyama, Ayane
Kubota, Takafumi
Ikeda, Kensuke
Kaneko, Kimihiko
Takai, Yoshiki
Warita, Hitoshi
Takahashi, Toshiyuki
Misu, Tatsuro
Aoki, Masashi
author_facet Matsumoto, Yuki
Ohyama, Ayane
Kubota, Takafumi
Ikeda, Kensuke
Kaneko, Kimihiko
Takai, Yoshiki
Warita, Hitoshi
Takahashi, Toshiyuki
Misu, Tatsuro
Aoki, Masashi
author_sort Matsumoto, Yuki
collection PubMed
description Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a newly identified autoimmune demyelinating disorder that is often associated with acute disseminated encephalomyelitis and usually occurs postinfection or postvaccination. Here we report a case of MOGAD after mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. A previously healthy 68-year-old woman presented to our department with gradually worsening numbness on the right side of her face, which began 14 days after her second dose of an mRNA-1273 vaccination. The patient's brain MRI revealed a right cerebellar peduncle lesion with gadolinium enhancement, a typical finding of MOGAD. A neurological examination revealed paresthesia on her right V2 and V3 areas. Other neurological examinations were unremarkable. Laboratory workups were positive for serum MOG-IgG as assessed by live cell-based assays and the presence of oligoclonal bands in the cerebrospinal fluid (CSF). The patient's serum test results for cytoplasmic-antineutrophil cytoplasmic antibodies, perinuclear-cytoplasmic-antineutrophil cytoplasmic antibodies, GQ1b-antibodies, and aquaporin-4 antibodies (AQP4-IgG) were all negative. Tests for soluble interleukin (IL)-2 receptors in the serum, IL-6 in the CSF and skin pricks, and angiotensin converting enzyme tests were all unremarkable. The patient was diagnosed with MOGAD after receiving an mRNA SARS-CoV-2 vaccination. After two courses of intravenous methylprednisolone treatment, the patient's symptoms improved and her cerebellar peduncle lesion shrunk slightly without gadolinium enhancement. To date, there have only been two cases of monophasic MOGAD following SARS-CoV-2 vaccination, including both the ChAdOx1 nCOV-19 and mRNA-1273 vaccines, and the prognosis is generally similar to other typical MOGAD cases. Although the appearance of MOG antibodies is relatively rare in post-COVID-19–vaccine demyelinating diseases, MOGAD should be considered in patients with central nervous system (CNS) demyelinating diseases after receiving a SARS-CoV-2 vaccine.
format Online
Article
Text
id pubmed-8922017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89220172022-03-16 MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review Matsumoto, Yuki Ohyama, Ayane Kubota, Takafumi Ikeda, Kensuke Kaneko, Kimihiko Takai, Yoshiki Warita, Hitoshi Takahashi, Toshiyuki Misu, Tatsuro Aoki, Masashi Front Neurol Neurology Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a newly identified autoimmune demyelinating disorder that is often associated with acute disseminated encephalomyelitis and usually occurs postinfection or postvaccination. Here we report a case of MOGAD after mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. A previously healthy 68-year-old woman presented to our department with gradually worsening numbness on the right side of her face, which began 14 days after her second dose of an mRNA-1273 vaccination. The patient's brain MRI revealed a right cerebellar peduncle lesion with gadolinium enhancement, a typical finding of MOGAD. A neurological examination revealed paresthesia on her right V2 and V3 areas. Other neurological examinations were unremarkable. Laboratory workups were positive for serum MOG-IgG as assessed by live cell-based assays and the presence of oligoclonal bands in the cerebrospinal fluid (CSF). The patient's serum test results for cytoplasmic-antineutrophil cytoplasmic antibodies, perinuclear-cytoplasmic-antineutrophil cytoplasmic antibodies, GQ1b-antibodies, and aquaporin-4 antibodies (AQP4-IgG) were all negative. Tests for soluble interleukin (IL)-2 receptors in the serum, IL-6 in the CSF and skin pricks, and angiotensin converting enzyme tests were all unremarkable. The patient was diagnosed with MOGAD after receiving an mRNA SARS-CoV-2 vaccination. After two courses of intravenous methylprednisolone treatment, the patient's symptoms improved and her cerebellar peduncle lesion shrunk slightly without gadolinium enhancement. To date, there have only been two cases of monophasic MOGAD following SARS-CoV-2 vaccination, including both the ChAdOx1 nCOV-19 and mRNA-1273 vaccines, and the prognosis is generally similar to other typical MOGAD cases. Although the appearance of MOG antibodies is relatively rare in post-COVID-19–vaccine demyelinating diseases, MOGAD should be considered in patients with central nervous system (CNS) demyelinating diseases after receiving a SARS-CoV-2 vaccine. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8922017/ /pubmed/35299613 http://dx.doi.org/10.3389/fneur.2022.845755 Text en Copyright © 2022 Matsumoto, Ohyama, Kubota, Ikeda, Kaneko, Takai, Warita, Takahashi, Misu and Aoki. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Matsumoto, Yuki
Ohyama, Ayane
Kubota, Takafumi
Ikeda, Kensuke
Kaneko, Kimihiko
Takai, Yoshiki
Warita, Hitoshi
Takahashi, Toshiyuki
Misu, Tatsuro
Aoki, Masashi
MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
title MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
title_full MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
title_fullStr MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
title_full_unstemmed MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
title_short MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review
title_sort mog antibody-associated disorders following sars-cov-2 vaccination: a case report and literature review
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922017/
https://www.ncbi.nlm.nih.gov/pubmed/35299613
http://dx.doi.org/10.3389/fneur.2022.845755
work_keys_str_mv AT matsumotoyuki mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT ohyamaayane mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT kubotatakafumi mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT ikedakensuke mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT kanekokimihiko mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT takaiyoshiki mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT waritahitoshi mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT takahashitoshiyuki mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT misutatsuro mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview
AT aokimasashi mogantibodyassociateddisordersfollowingsarscov2vaccinationacasereportandliteraturereview